www.bioscience.co.uk
Sales & Support: +44 (0)1223 316 855

BioXCell bispecific antibodies

Bispecific antibodies are an advanced class of biologics engineered to recognise and bind two distinct antigens or epitopes simultaneously. By bridging cellular interactions or co‑targeting molecular pathways, BioXCell's in vivo-ready bispecifics offer a powerful strategy for immune cell redirection, dual‑pathway blockade, payload delivery, and enhanced selectivity.

In drug discovery and translational research, bispecific antibodies are increasingly used to:

  • Redirect T cells or NK cells for targeted cytotoxicity
  • Engage multiple immune checkpoints
  • Block redundant or compensatory signalling pathways
  • Improve tumour specificity and reduce off‑target effects
  • Explore novel immune‑therapeutic mechanisms in oncology, autoimmunity, and infectious disease

 

BioXCell’s curated bispecific antibody portfolio offers multiple formats and is designed to support the rapid development and validation of innovative therapeutic concepts, offering high‑purity, in vivo-grade reagents backed by the quality standards researchers expect.

  • Anti-mouse bispecific antibodies: purpose-built, in vivo-ready bispecific reagents optimised for murine studies, closely modeled on clinical formats to support reliable mechanism‑of‑action and efficacy insights.
  • Anti-human bispecific biosimilars: high-fidelity biosimilar bispecifics engineered to reflect therapeutic antibodies, enabling precise benchmarking and translational validation from discovery through development.
  • Custom bispecific engineering: tailored bispecific antibody design backed by expert scientific guidance and scalable manufacturing solutions, accelerating advancement of bispecific pipelines.

 

contact our BioXCell specialists

BioXCell’s bispecific solutions

  • Mouse-specific bispecific antibodies provide researchers the tools they need for mouse models, without having to invest in expensive humanised mice.
  • Biosimilars of clinical bispecifics enable research comparisons with therapeutic formats
  • Bispecifics are dual-target validated, high purity and in vivo ready, allowing researchers to run studies immediately without waiting for custom constructs
  • Consistent, low endotoxin, reproducible bispecifics reduce experimental variability, helping researchers generate cleaner data faster, lowering risk and accelerating go/no-go decisions
  • Researchers can use ready to ship bispecifics or choose custom services.

 

Target pair Therapeutic analogue Species Applications
CD3 x BCMA Teclistamab Human Preclinical modeling of bispecific T-cell engager activity in multiple myeloma.
CD3 x GPRC5D Talquetamab Human Evaluating dual-targeting strategies for resistant myeloma and T-cell redirection.
EGFR x MET Amivantamab Human Studying receptor crosstalk, ligand competition, and resistance mechanism in epithelial tumors.
CD3 x CD20 Epcortimab* Mouse Investigating dual B-cell targeting and T-cell engagement in syngeneic lymphoma models.
PD-1 x VEGF Ivonescimab* Mouse Modeling immune checkpoint and angiogenic pathway interplay in mouse tumor studies.

 

*Engineered mouse bispecifics designed to dually target murine antigens corresponding to the therapeutic targets listed above.

Material for download

BioXCell bispecific antibodies brochure

BioXCell bispecific antibodies product flyer

Products

Note: product availability depends on country - see product detail page.

Details Cat number & supplier Size Price
Bispecific anti-mouse PD-1 x anti-mouse VEGF-A (LALA-PG) CPB501-25MG · Bio X Cell
CPB501-25MG
Bio X Cell
25 mg £42591.00
25 mg
view
Bispecific mouse IgG2a (LALA-PG)-scFv, kappa isotype control CPB500-25MG · Bio X Cell
CPB500-25MG
Bio X Cell
25 mg £42591.00
25 mg
view
InVivoSIM anti-human CD3 x BCMA (Teclistamab Biosimilar) SIM0067-R025mg · Bio X Cell
SIM0067-R025mg
Bio X Cell
25 mg £5540.00
25 mg
view
InVivoSIM anti-human CD3 x GPRC5D (Talquetamab Biosimilar) SIM0069-R050mg · Bio X Cell
SIM0069-R050mg
Bio X Cell
50 mg £8202.00
50 mg
view
InVivoSIM anti-human EGFR x MET (Amivantamab Biosimilar) SIM0081-R050mg · Bio X Cell
SIM0081-R050mg
Bio X Cell
50 mg £8202.00
50 mg
view
InVivoSIM anti-human CD3 x BCMA (Teclistamab Biosimilar) SIM0067-R050mg · Bio X Cell
SIM0067-R050mg
Bio X Cell
50 mg £7963.00
50 mg
view
InVivoSIM anti-human CD3 x BCMA (Teclistamab Biosimilar) SIM0067-R100mg · Bio X Cell
SIM0067-R100mg
Bio X Cell
100 mg £14172.00
100 mg
view
InVivoSIM anti-human CD3 x GPRC5D (Talquetamab Biosimilar) SIM0069-R100mg · Bio X Cell
SIM0069-R100mg
Bio X Cell
100 mg £14598.00
100 mg
view
InVivoSIM anti-human EGFR x MET (Amivantamab Biosimilar) SIM0081-R100mg · Bio X Cell
SIM0081-R100mg
Bio X Cell
100 mg £14598.00
100 mg
view